IDH2 and myelodysplastic syndrome: Another ongoing study (NCT03839771), a phase III multicenter, double blind, randomized, placebo-controlled study, is also evaluating the efficacy of ivosidenib and enasidenib in combination with intensive induction therapy, consolidation therapy, and maintenance therapy in patients with AML or myelodysplastic syndrome (MDS) with excess blasts-2 with an IDH1 or IDH2 mutation.